Pharma Uncertainty Remains As UK Votes To Delay Brexit
UK members of parliament have ruled out a no-deal Brexit and voted to request a delay to the exit date, and they will vote again on the withdrawal deal next week. But all this just serves to exacerbate the uncertainty and frustration felt by businesses working in the pharmaceutical sector.
You may also be interested in...
Steve Bates, CEO of the UK BioIndustry Association, tries to untangle the increasingly chaotic Brexit process and establish how the various scenarios might pan out for the life sciences industry.
A European firm with significant operations in the UK, Norgine has invested considerable resources in preparing for Brexit. With less than three weeks to go before the UK is scheduled to leave the EU, chief operating officer Peter Martin is very concerned about the risks of a no-deal Brexit, and the lack of clarity on what will happen next.
A recent debate in the House of Lords saw some fiery words exchanged over the government’s plans for the life science sector in the event of a no-deal Brexit, with accusations that they would produce a “clunky” regulatory system and put industry’s future “at grave risk.”